About Accelmed
Accelmed is a private equity firm founded in 2009. It is primarily based in Miami, United States. As of Jun 2026, Accelmed is an active investor with a portfolio of 33 companies, comprising 33 funding rounds and 2 acquisitions. In the last 12 months, it has participated in 1 funding round. The firm primarily invests in companies based in United States and Israel. Its portfolio is spread across a wide range of sectors from Life Sciences to HealthTech. Its latest investment was a $***** Series D round in Corvia Medical on Jun 12, 2025 which also saw participation from Third Rock Ventures, General Catalyst and other investors.
A lot of funds co-invest with Accelmed, with names like Revelation Partners sharing a substantial percentage of its portfolio.
Accelmed has a team of 13 people, including 7 partners.
Key Metrics
Founded Year
2009
Location
Miami, United States
Portfolio Companies
Portfolio Sectors
Portfolio Locations
Acquisition Deals
Investment Deals
Accelmed's Portfolio
Accelmed has a portfolio of 33 companies. They have invested in a total of 33 companies. Their most recent investment was in Corvia Medical (Series D round) on Jun 12, 2025. Here are the most recent investments by Accelmed:Date | Company | Round | Amount | Co-Investors |
|---|---|---|---|---|
Jun 12, 2025 | Series D | 9412 | ||
May 30, 2025 | Series B | 1442 | ||
May 29, 2025 | Series B | 1100 | ||
Dec 23, 2024 | Series D | 3536 |
Accelmed has acquired 2 companies. Their most recent acquisition was of TearLab on May 11, 2020. Here are the most recent acquisitions by Accelmed:
Acquisition Date | Company | Short Description | Total Funding | Founded Year |
|---|---|---|---|---|
May 11, 2020 | Developer of diagnostic tests for detecting hyperosmolarity | - | 2003 | |
Jun 04, 2018 | Dental solutions provider: implants, biomaterials, prosthetics, instruments, and planning software | $86.2M | 2006 |
Here is the portfolio snapshot of Accelmed:
Investments by Year
The maximum number of investments were made in 2025
Acquisitions by Year
The maximum number of acquisitions were made in 2020
Portfolio by Location
Companies are primarily in United States and Israel
Portfolio by Sector
Companies are primarily in Life Sciences
Team profile of Accelmed
Accelmed has a team of 13 members including 7 Partners, 1 Venture Partner and 2 Principals located in Israel and United States. Accelmed's team sits on the board of 2 companies.Here is a list of top team members in Accelmed:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Israel | |||
Partner | Israel | - | ||
Partner | Israel | - | - | |
Partner | New York City | - | - | |
Partner | Israel | - | - | |
Partner | - | - | - | |
Partner | New York Mills | - | - | |
Venture Partner | Israel | - | ||
Principal | Miami | |||
Principal | Philadelphia | - |
Co-investors of Accelmed
Over the past 17 years, 30 investors have co-invested in Accelmed's portfolio companies.
- Top Co-investors of Accelmed: 30 investors entered a company along with Accelmed. These include investors like Revelation Partners (2 companies).
Accelmed News
•
Corvia Medical secures $55M funding to complete trial and pursue FDA approval for Atrial Shuntintelligence360•Jun 30, 2025•Corvia Medical, Lumira Ventures, Accelmed, General Catalyst and 1 other
•
Acclaro Medical Secures $23 Million in Series B Funding Led by Accelmed Partnersintelligence360•Jun 09, 2025•Acclaro Medical, Accelmed, 3E Bioventures Capital
•
•
•
GT Medical Technologies Raises $37M in Series D FundingFinSMEs•Jan 16, 2025•GT Medical Technologies, Evidity Health Capital, Accelmed, MVM and 2 others
•
Bioventus Completes Divestiture of its Advanced Rehabilitation Business to Accelmed PartnersGlobeNewswire•Jan 02, 2025•Bioventus, Accelmed
•
TailorMed raises $40 million in equity and debt to help patients access critical medicationsCTech•Nov 21, 2024•TailorMed, Windham Venture Partners, Samsung NEXT, Citi and 17 others
•
Bioventus announces divestiture of its Advanced Rehabilitation business to Accelmed PartnersSeeking Alpha•Oct 01, 2024•Bioventus, Accelmed
•
•
